A carregar...
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup
BACKGROUND: Lumacaftor/ivacaftor combination therapy demonstrated clinical benefits in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. Pretreatment lung function is a confounding factor that potentially impacts the efficacy and safety of lumacaftor/ivacaftor therapy. METHOD...
Na minha lista:
| Publicado no: | Lancet Respir Med |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6612264/ https://ncbi.nlm.nih.gov/pubmed/27298017 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-2600(16)30121-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|